New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Dare Bioscience, Inc. (DARE) vs CytoMed Therapeutics Limited (GDTC)

Dare Bioscience, Inc. and CytoMed Therapeutics Limited are both Biotechnology companies. Dare Bioscience, Inc. and CytoMed Therapeutics Limited are of similar size ($9.2M and $8.9M). Across the 7 metrics below, CytoMed Therapeutics Limited leads on 6 and Dare Bioscience, Inc. on 1.

Valuation

Metric DARE GDTC Biotechnology median
P/E n/m n/m 8.49
P/S 5.06 — 8.56
P/B 3.05 0.51 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.52 n/m 0.69
EV/Sales (3.11) — 8.00
Earnings yield (166.32%) (35.90%) (35.81%)
Free cash flow yield (257.09%) (0.43%) (25.41%)

Profitability

Metric DARE GDTC Biotechnology median
Gross margin 47.37% — 70.18%
Operating margin (746.14%) — 0.00%
Net margin (749.83%) — 0.00%
Free cash flow margin — — 0.00%
Return on equity (407.13%) — (51.58%)
Return on assets (40.05%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric DARE GDTC Biotechnology median
Revenue growth (TTM) 2,571.63% — 7.20%
EPS growth (last fiscal year) (150.00%) (68.75%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric DARE GDTC Biotechnology median
Debt to equity 0.00 80.30 0.00
Current ratio 1.23 2.64 4.79
Net debt to EBITDA 2.07 0.86 1.01

Dividend

Metric DARE GDTC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DARE GDTC Biotechnology median
Market cap 8.89m 9.15m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack